提吉特
转录组
癌症研究
生物
CD8型
细胞毒性T细胞
免疫检查点
肝癌
T细胞
抗体
免疫系统
免疫学
免疫疗法
肝细胞癌
基因表达
基因
遗传学
体外
作者
Dmitrij Ostroumov,Steven Duong,Jessica Wingerath,Norman Woller,Michael P. Manns,Kai Timrott,Moritz Kleine,Wolf Ramackers,Stephanie Roessler,Sven Nahnsen,Stefan Czemmel,Oliver Dittrich‐Breiholz,Tobias Eggert,Florian Kühnel,Thomas Wirth
出处
期刊:Hepatology
[Lippincott Williams & Wilkins]
日期:2021-04-01
卷期号:73 (4): 1399-1418
被引量:75
摘要
Programmed death 1 (PD-1) checkpoint inhibition has shown promising results in patients with hepatocellular carcinoma, inducing objective responses in approximately 20% of treated patients. The roles of other coinhibitory molecules and their individual contributions to T-cell dysfunction in liver cancer, however, remain largely elusive.We performed a comprehensive mRNA profiling of cluster of differentiation 8 (CD8) T cells in a murine model of autochthonous liver cancer by comparing the transcriptome of naive, functional effector, and exhausted, tumor-specific CD8 T cells. Subsequently, we functionally validated the role of identified genes in T-cell exhaustion. Our results reveal a unique transcriptome signature of exhausted T cells and demonstrate that up-regulation of the inhibitory immune receptor T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitor motif domains (TIGIT) represents a hallmark in the process of T-cell exhaustion in liver cancer. Compared to PD-1, expression of TIGIT more reliably identified exhausted CD8 T cells at different stages of their differentiation. In combination with PD-1 inhibition, targeting of TIGIT with antagonistic antibodies resulted in synergistic inhibition of liver cancer growth in immunocompetent mice. Finally, we demonstrate expression of TIGIT on tumor-infiltrating CD8 T cells in tissue samples of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma and identify two subsets of patients based on differential expression of TIGIT on tumor-specific T cells.Our transcriptome analysis provides a valuable resource for the identification of key pathways involved in T-cell exhaustion in patients with liver cancer and identifies TIGIT as a potential target in checkpoint combination therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI